{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:11:56Z","timestamp":1775059916088,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00432-022-04379-2","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T05:02:33Z","timestamp":1664600553000},"page":"2637-2645","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ten years of AMNOG from an oncological perspective: new horizons and continuing expansion"],"prefix":"10.1007","volume":"149","author":[{"given":"Arne","family":"Bartol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kaskel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Landsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Petschulies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,1]]},"reference":[{"key":"4379_CR1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1237-4011","author":"C Apfelbacher","year":"2020","unstructured":"Apfelbacher C et al (2020) Manual for methods and use of routine practice data for knowledge generation. Das Gesundheitswesen. https:\/\/doi.org\/10.1055\/a-1237-4011","journal-title":"Das Gesundheitswesen"},{"key":"4379_CR2","unstructured":"Association of Research-Based Pharmaceutical Companies (2021) Press release\u2014Germany is quick. Association of Research-Based Pharmaceutical Companies. https:\/\/www.vfa.de\/de\/presse\/pressemitteilungen\/pm-009-2021-deutschland-ist-schnell.html. Accessed 10 Aug 2021"},{"key":"4379_CR3","unstructured":"Bundesanzeiger (2010) Act to reorganize the pharmaceuticals\u2019 market in the statutory health insurance. Bundesanzeiger Verlag. http:\/\/www.bgbl.de\/xaver\/bgbl\/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl110s2262.pdf. Accessed 10 Aug 2021"},{"key":"4379_CR4","unstructured":"Bundesanzeiger (2012) Second act amending pharmaceutical and other regulations. Bundesanzeiger Verlag. http:\/\/www.bgbl.de\/xaver\/bgbl\/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl112s2192.pdf. Accessed 16 Aug 2021"},{"key":"4379_CR5","unstructured":"Bundesanzeiger (2017) Act to strengthen the supply of medicines in the statutory health insurance. Bundesanzeiger Verlag. http:\/\/www.bgbl.de\/xaver\/bgbl\/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl117s1050.pdf. Accessed 10 Aug 2021"},{"key":"4379_CR6","unstructured":"Bundesanzeiger (2019) Act for more safety in the supply of pharmaceuticals. Bundesanzeiger Verlag. http:\/\/www.bgbl.de\/xaver\/bgbl\/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1202.pdf. Accessed 16 Aug 2021"},{"key":"4379_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/2191-1991-4-2","author":"I Dabisch","year":"2014","unstructured":"Dabisch I et al (2014) Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany. Health Econ Rev. https:\/\/doi.org\/10.1186\/2191-1991-4-2","journal-title":"Health Econ Rev"},{"key":"4379_CR8","unstructured":"Federal Joint Committee (2013) Supporting evidence for the decision of the Federal Joint Committee on an amendment to the Pharmaceuticals Guideline (AM-RL): Annex XII\u2014Decisions on the benefit assessment of medicinal products with new active substances according to \u00a7 35a SGB V Crizotinib. Federal Joint Committee. https:\/\/www.g-ba.de\/downloads\/40-268-2301\/2013-05-02_AM-RL-XII_Crizotinib_TrG.pdf. Accessed 10 Aug 2021"},{"key":"4379_CR9","unstructured":"Federal Joint Committee (2018) Benefit assessment according to \u00a7 35a SGB V-Benefit assessment procedure for the active substance Carfilzomib (exceedance of \u20ac 50 million threshold: multiple myeloma, at least 1 prior therapy, combination with Dexamethasone or Lenalidomide and Dexamethasone). Federal Joint Committee. https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/308\/. Accessed 10 Aug 2021"},{"key":"4379_CR10","unstructured":"Federal Joint Committee (2019a) Benefit assessment according to \u00a7 35a SGB V\u2014benefit assessment procedure for the active substance Pembrolizumab (new indication: melanoma, adjuvant therapy). Federal Joint Committee. https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/451\/. Accessed 10 Aug 2021"},{"key":"4379_CR11","unstructured":"Federal Joint Committee (2019b) Benefit assessment according to \u00a7 35a SGB V\u2014Benefit assessment procedure for the active substance Trametinib (new indication: melanoma, in combination with Dabrafenib, BRAF V600 mutation, adjuvant therapy). Federal Joint Committee. https:\/\/www.gba.de\/bewertungsverfahren\/nutzenbewertung\/387\/. Accessed 10 Aug 2021"},{"key":"4379_CR12","unstructured":"Federal Joint Committee (2019c) Benefit assessment according to \u00a7 35a SGB V - Benefit assessment procedure for the active substance Brentuximab Vedotin (new indication: systemic anaplastic large cell lymphoma; first-line; combination with Cyclophosphamide, Doxorubicin and Prednisone). Federal Joint Committee. https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/557\/. Accessed 16 Sep 2021"},{"key":"4379_CR13","unstructured":"Federal Joint Committee (2019d) Supporting evidence for the decision of the Federal Joint Committee on an amendment to the German Medicines Directive (AM-RL): Annex XII\u2014Benefit assessment of medicinal products with new active substances according to Section 35a SGB V Pembrolizumab (new indication: non-small cell lung cancer, non-plate epithelial, first-line, combination with pemetrexed and platinum chemotherapy). Federal Joint Committee. https:\/\/www.g-ba.de\/downloads\/40-268-6021\/201.9-09-19_AM-RL-XII_Pembrolizumab_D-447_TrG.pdf. Accessed 10 Aug 2021"},{"key":"4379_CR14","unstructured":"Federal Joint Committee (2020a) Benefit assessment according to \u00a7 35a SGB V\u2014Benefit assessment procedure for the active substance Larotrectinib (solid tumors, neurotrophic tyrosine receptor kinase (NTRK) gene fusion, histology-independent). Federal Joint Committee. https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/502\/. Accessed 17 Aug 2021"},{"key":"4379_CR15","unstructured":"Federal Joint Committee (2020b) Resolution\u2014rules of procedure: procedure for requesting a register study. Federal Joint Committee. https:\/\/www.g-ba.de\/beschluesse\/4402\/. Accessed 10 Aug 2021"},{"key":"4379_CR16","unstructured":"Federal Joint Committee (2021a) Additional benefit of new drugs \u2013 Categories. Federal Joint Committee. https:\/\/www.g-ba.de\/themen\/arzneimittel\/arzneimittel-richtlinie-anlagen\/nutzenbewertung-35a\/zusatznutzen\/. Accessed 16 Aug 2021a"},{"key":"4379_CR17","unstructured":"Federal Joint Committee (2021b) Annual Report 2020. Federal Joint Committee. https:\/\/www.g-ba.de\/downloads\/17-98-5148\/202.1-07-01_G-BA_Geschaeftsbericht_2020_bf.pdf. Accessed 10 Aug 2021b"},{"key":"4379_CR18","unstructured":"Federal Joint Committee (2021c) Benefit assessment according to Section 35a SGB V - Benefit assessment procedure for the active substance Entrectinib (solid tumors, neurotrophic tyrosine receptor kinase (NTRK) gene fusion, histology-independent). Federal Joint Committee. https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/588\/#beschluesse-mobile. Accessed 17 Aug 2021c"},{"key":"4379_CR19","unstructured":"Federal Joint Committee (2021d) Decision of benefit assessment of August 20 2020\u2014from minute 47.20. Federal Joint Committee. https:\/\/www.g-ba.de\/service\/livestream-mediathek\/. Accessed 16 Sep 2021d"},{"key":"4379_CR20","unstructured":"Federal Joint Committee (2021e) Resolution\u2014Measures regarding quality assurance according to \u00a7 136a paragraph 5 SGB V: CAR-T cells in B cell neoplasms and on the amendment of Annex XII. Federal Joint Committee. https:\/\/www.g-ba.de\/beschluesse\/4477\/. Accessed 16 Sep 2021e"},{"key":"4379_CR21","unstructured":"Institute for Quality and Efficiency in Health Care (2020) General methods\u2014version 6.0 of 5 November 2020. Institute for Quality and Efficiency in Health Care. https:\/\/www.iqwig.de\/methoden\/general-methods_version-6-0.pdf. Accessed 10 Aug 2021"},{"key":"4379_CR22","unstructured":"Tr\u00fcmper L, W\u00f6rmann B (2021) Early benefit assessment of new drugs in Germany 2011\u20132020\u2014pricing and more. German Society for Haematology and Medical Oncology (DGHO) and Association of the Scientific Medical Societies in Germany (AWMF). https:\/\/www.dgho.de\/publikationen\/schriftenreihen\/fruehe-nutzenbewertung\/awmf_amnog_2021_210x297_ok_ansicht_es.pdf. Accessed 16 Aug 2021"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04379-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04379-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04379-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:21:19Z","timestamp":1744204879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04379-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["4379"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04379-2","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,1]]},"assertion":[{"value":"8 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AB is an employee of Janssen-Cilag GmbH, Neuss, Germany; KD is an employee of Bayer Vital GmbH, Berlin, Germany; at the time of the concept development and realization, PK was an employee of MSD Sharp & Dohme GmbH (a German subsidiary of Merck & Co., Inc., Rahway, NJ, USA), and is a shareholder in Merck & Co., Inc., Rahway, NJ, USA); CL is an employee of Novartis Pharma GmbH; CL is an employee of Amgen GmbH; MP is a full-time employee of Takeda Pharma Vertrieb GmbH & Co. KG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable\u2014no clinical study was conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable\u2014no clinical study was conducted.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable\u2014no clinical study was conducted.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}